APA (7th ed.) Citation

S, S., N, A., OS, A., R, B., T, O., M, B., . . . MC, P. (2025). Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood, 146(2), 167. https://doi.org/10.1182/blood.2024026216

Chicago Style (17th ed.) Citation

S, Sidana, et al. "Standard-of-care Idecabtagene Vicleucel for Relapsed/refractory Multiple Myeloma." Blood 146, no. 2 (2025): 167. https://doi.org/10.1182/blood.2024026216.

MLA (9th ed.) Citation

S, Sidana, et al. "Standard-of-care Idecabtagene Vicleucel for Relapsed/refractory Multiple Myeloma." Blood, vol. 146, no. 2, 2025, p. 167, https://doi.org/10.1182/blood.2024026216.